{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:29:56Z","timestamp":1793147396788,"version":"4.5.0"},"reference-count":56,"publisher":"Oceanside Publications Inc.","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Hereditary angioedema (HAE) substantially impairs patients\u2019 quality of life (QoL), both physically and psychologically, with unpredictable attacks that cause disruptions in education, work, and social life.  <jats:bold>Objective:<\/jats:bold> To identify key\n themes and existing knowledge gaps around the multifaceted burden of HAE.  <jats:bold>Methods:<\/jats:bold> A literature review was conducted in January 2024 through a search of medical literature data bases. English-language studies considered relevant to patient burden and QoL were selected for\n analysis.  <jats:bold>Results:<\/jats:bold> A total of 48 studies were included in the analysis; 50% were cross-sectional and 54% were conducted in North America. Twenty-three studies reported outcomes on QoL and pain, 10 studies reported outcomes on psychological distress, 16 studies reported\n outcomes on experiences with long-term prophylaxis, 36 studies reported outcomes on HAE attacks, and one study detailed caregiver burden. Patients with HAE had worse QoL compared with the general population, and worse QoL was associated with a higher frequency or severity of attacks, anxiety,\n and depression. The use of long-term prophylaxis improved QoL, and treatment satisfaction was driven by improvements in mental health and fostering a sense of control and independence.  <jats:bold>Conclusion:<\/jats:bold> HAE continues to substantially impact QoL of patients. Although recent work\n has demonstrated progress in standardizing assessment tools for QoL in HAE, additional research is needed to determine the correlation between individual patient factors and QoL.<\/jats:p>","DOI":"10.2500\/aap.2025.46.250048","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T04:36:17Z","timestamp":1758083777000},"page":"398-405","source":"Crossref","is-referenced-by-count":11,"title":["Quality of life and burden of disease in patients with hereditary angioedema and their caregivers"],"prefix":"10.2500","volume":"46","author":[{"given":"Donald S.","family":"Levy","sequence":"first","affiliation":[{"name":"From the University of California Irvine, Orange, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda I.","family":"Nagase","sequence":"additional","affiliation":[{"name":"Broadstreet Health Economics and Outcomes Research, Vancouver, British Columbia, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"Cheung","sequence":"additional","affiliation":[{"name":"Broadstreet Health Economics and Outcomes Research, Vancouver, British Columbia, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre A.","family":"Rodeberg","sequence":"additional","affiliation":[{"name":"MedThink SciCom, Raleigh, North Carolina; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Manning","sequence":"additional","affiliation":[{"name":"Allergy, Asthma, and Immunology Associates, Scottsdale, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.12968\/hmed.2019.80.7.391","article-title":"Hereditary angioedema: an update on causes, manifestations and treatment","volume":"80","author":"Longhurst","year":"2019","journal-title":"Br J Hosp Med (Lond)"},{"key":"B2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.amjmed.2005.09.064","article-title":"Hereditary angioedema: new findings concerning symptoms, affected organs, and course","volume":"119","author":"Bork","year":"2006","journal-title":"Am J Med"},{"key":"B4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fmed.2017.00212","article-title":"Disease severity, activity, impact, and control and how to assess them in patients with hereditary angioedema","volume":"4","author":"Bygum","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"B5","doi-asserted-by":"crossref","first-page":"100758","DOI":"10.1016\/j.waojou.2023.100758","article-title":"A narrative review of recent literature of the quality of life in hereditary angioedema patients","volume":"16","author":"Chong-Neto","year":"2023","journal-title":"World Allergy Organ J"},{"key":"B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13223-021-00563-0","article-title":"Psychosocial burden of type 1 and 2 hereditary angioedema: a single-center Canadian cohort study","volume":"17","author":"Hews-Girard","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13223-016-0176-3","article-title":"Hereditary angioedema: health-related quality of life in Canadian patients as measured by the SF-36","volume":"13","author":"Jindal","year":"2017","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12016-021-08850-9","article-title":"How angioedema quality of life questionnaire can help physicians in treating C1-inhibitor deficiency patients?","volume":"61","author":"Balla","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2500\/aap.2017.38.4087","article-title":"Health-related quality of life in relation to disease activity in adults with hereditary angioedema in Sweden","volume":"38","author":"Nordenfelt","year":"2017","journal-title":"Allergy Asthma Proc"},{"key":"B10","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.anai.2021.01.002","article-title":"Quality of life in patients with hereditary angioedema in Canada","volume":"126","author":"Lee","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2500\/aap.2021.42.200127","article-title":"Assessing the cost and quality-of-life impact of on-demand\u2010only medications for adults with hereditary angioedema","volume":"42","author":"Castaldo","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"B12","first-page":"106","article-title":"Understanding the impact of HAE attacks on patient reported quality-of-life\u2014analysis of real-world patient data","volume":"19","author":"Hinds","year":"2023","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.anai.2020.02.018","article-title":"Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States","volume":"124","author":"Banerji","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2500\/aap.2010.31.3394","article-title":"The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression","volume":"31","author":"Lumry","year":"2010","journal-title":"Allergy Asthma Proc"},{"key":"B15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13223-021-00550-5","article-title":"Letting the patients speak: an in-depth, qualitative research-based investigation of factors relevant to health-related quality of life in real-world patients with hereditary angioedema using subcutaneous C1 inhibitor replacement therapy","volume":"17","author":"Anderson","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B16","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1016\/j.jaip.2021.04.072","article-title":"Lanadelumab efficacy, safety, and injection interval extension in HAE: a real-life study","volume":"9","author":"Buttgereit","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B17","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1016\/j.jaip.2021.08.019","article-title":"Racial and ethnic disparities in the research and care of hereditary angioedema patients in the United States","volume":"9","author":"Sylvestre","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.anai.2013.05.028","article-title":"Depression and anxiety in patients with hereditary angioedema","volume":"112","author":"Fouche","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"AB136","DOI":"10.1016\/j.jaci.2022.12.424","article-title":"Comparison of selected health and well being characteristics in seniors with hereditary angioedema (HAE) and a non-HAE patient matched cohort","volume":"151","author":"Castaldo","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.anai.2023.10.011","article-title":"Hereditary angioedema in older adults: understanding the patient perspective","volume":"132","author":"Baptist","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B21","doi-asserted-by":"crossref","first-page":"101339","DOI":"10.1016\/j.ienj.2023.101339","article-title":"Hereditary angioedema patient experiences of medication use and emergency care","volume":"71","author":"Burton","year":"2023","journal-title":"Int Emerg Nurs"},{"key":"B22","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2500\/aap.2021.42.210025","article-title":"Patient perspectives on the treatment burden of injectable medication for hereditary angioedema","volume":"42","author":"Radojicic","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"B23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13223-023-00861-9","article-title":"Patient outcomes associated with subcutaneous C1INH prophylaxis for hereditary angioedema: a retrospective analysis","volume":"19","author":"Lumry","year":"2023","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.anai.2017.05.017","article-title":"Patient satisfaction and experience with intravenously administered C1-inhibitor concentrates in the United States","volume":"119","author":"Riedl","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B25","doi-asserted-by":"crossref","first-page":"e0260805","DOI":"10.1371\/journal.pone.0260805","article-title":"How do patients and physicians communicate about hereditary angioedema in the United States?","volume":"16","author":"Jain","year":"2021","journal-title":"PLoS One"},{"key":"B26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1081-1206(10)60424-3","article-title":"Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients","volume":"100","author":"Bork","year":"2008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1684\/ejd.2008.0603","article-title":"Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits","volume":"19","author":"Bygum","year":"2009","journal-title":"Eur J Dermatol"},{"key":"B28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/21556660.2020.1863699","article-title":"Hereditary angioedema patients would prefer newer-generation oral prophylaxis","volume":"10","author":"Geba","year":"2021","journal-title":"J Drug Assess"},{"key":"B29","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.2500\/aap.2021.42.210017","article-title":"Physician and patient perspectives on the management of hereditary angioedema: a survey on treatment burden and needs","volume":"42","author":"Riedl","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"B30","article-title":"People living with hereditary angioedema (HAE) prioritize attack-free status as a target for therapeutic efficacy","author":"Friedhoff"},{"key":"B31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2500\/aap.2015.36.3824","article-title":"Current state of hereditary angioedema management: a patient survey","volume":"36","author":"Banerji","year":"2015","journal-title":"Allergy Asthma Proc"},{"key":"B32","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.jaip.2023.03.032","article-title":"The disease burden and societal costs of hereditary angioedema","volume":"11","author":"Fijen","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5604\/01.3001.0014.0619","article-title":"Life-threatening laryngeal attacks in hereditary angioedema patients","volume":"74","author":"Piotrowicz-W\u00f3jcik","year":"2020","journal-title":"Otolaryngol Pol"},{"key":"B34","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.anai.2010.01.024","article-title":"Economic costs associated with acute attacks and long-term management of hereditary angioedema","volume":"104","author":"Wilson","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B35","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2500\/aap.2022.43.210104","article-title":"How satisfactory is on-demand icatibant from the patients' perspective in real life?","volume":"43","author":"Beyaz","year":"2022","journal-title":"Allergy Asthma Proc"},{"key":"B36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.anai.2021.07.015","article-title":"Demographic and clinical characteristics of patients with hereditary angioedema in Canada","volume":"128","author":"Lee","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B37","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.anai.2023.08.012","article-title":"The US Hereditary Angioedema Association Scientific Registry: hereditary angioedema demographics, disease severity, and comorbidities","volume":"131","author":"Christiansen","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B38","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jaci.2012.05.055","article-title":"Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency","volume":"130","author":"Bork","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B39","doi-asserted-by":"crossref","first-page":"258","DOI":"10.5336\/medsci.2021-81334","article-title":"5-year experience at a single center: retrospective analysis of 38 patients with hereditary angioedema: a descriptive study","volume":"41","author":"Aytekin","year":"2021","journal-title":"Turkiye Klinikleri J Med Sci."},{"key":"B40","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13223-023-00783-6","article-title":"National survey on clinical and genetic characteristics of patients with hereditary angioedema in Latvia","volume":"19","author":"Kanepa","year":"2023","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B41","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1054773818780102","article-title":"The diagnosis of hereditary angioedema: family caregivers\u2019 experiences","volume":"29","author":"Granero-Molina","year":"2020","journal-title":"Clin Nurs Res"},{"key":"B42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2500\/aap.2015.36.3831","article-title":"Before and after, the impact of available on-demand treatment for HAE","volume":"36","author":"Christiansen","year":"2015","journal-title":"Allergy Asthma Proc"},{"key":"B43","article-title":"Evolution of health-related quality of life in patients with hereditary angioedema due to c1-inhibitor deficiency (HAE-C1-INH) and its relationship with disease activity","author":"Fern\u00e1ndez","year":"2023","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B44","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13023-022-02202-2","article-title":"Psychometric study of the SF-36v2 in hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE)","volume":"17","author":"Palao-Ocharan","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13023-018-0797-3","article-title":"Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert\u00ae) in patients with hereditary angioedema: the SABHA study","volume":"13","author":"Zanichelli","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"B46","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2500\/aap.2023.44.230026","article-title":"Healthcare utilization of patients with hereditary angioedema treated with lanadelumab and subcutaneous C1-inhibitor concentrate","volume":"44","author":"Riedl","year":"2023","journal-title":"Allergy Asthma Proc"},{"key":"B47","doi-asserted-by":"crossref","first-page":"106216","DOI":"10.1016\/j.intimp.2020.106216","article-title":"Evaluation of the efficacy and safety of home treatment with the recombinant human C1-inhibitor in hereditary angioedema resulting from C1-inhibitor deficiency","volume":"80","author":"Andr\u00e1si","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B48","article-title":"Real-world effectiveness data on lanadelumab in HAE long term prophylaxis in Slovakia","author":"Je\u0161enak","year":"2023","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B49","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2500\/aap.2021.42.210015","article-title":"Etiology and predictors of cluster attacks of hereditary angioedema that recur despite pharmaceutical treatment","volume":"42","author":"Johnson","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"B50","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/11597490-000000000-00000","article-title":"Content validity of visual analog scales to assess symptom severity of acute angioedema attacks in adults with hereditary angioedema: an interview study","volume":"5","author":"McMillan","year":"2012","journal-title":"Patient"},{"key":"B51","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jaip.2021.09.046","article-title":"Clinical features and burden of genital attacks in hereditary angioedema","volume":"10","author":"Mormile","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B52","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2500\/aap.2015.36.3832","article-title":"Current characteristics associated with hereditary angioedema attacks and treatment: the home infusion based patient experience","volume":"36","author":"Tachdjian","year":"2015","journal-title":"Allergy Asthma Proc"},{"key":"B53","article-title":"Recombinant human C1 esterase inhibitor on-demand treatment for attacks of hereditary angioedema: a European registry update","volume":"19","author":"Valerieva","year":"2023","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B54","doi-asserted-by":"crossref","DOI":"10.2500\/aap.2020.41.200050","article-title":"Hereditary angioedema: epidemiology and burden of disease","volume":"41","author":"Lumry","year":"2020","journal-title":"Allergy Asthma Proc"},{"key":"B55","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12016-021-08854-5","article-title":"Mitigating disparity in health-case resources between countries for management of hereditary angioedema","volume":"61","author":"Jindal","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B56","article-title":"Quality of life and burden of disease in patients with hereditary angioedema and their caregivers","volume":"133(suppl)","author":"Levy","year":"2024","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2025\/00000046\/00000005\/art00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T04:39:00Z","timestamp":1759552740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2025.46.250048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9,1]]}},"alternative-id":["1088-5412(20250901)46:5L.398;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2025.46.250048","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}